Search Results for: 19

— Company Focused on Novel Anti-Infectives for the Prevention and Treatment of Serious Infectious Diseases — — Conference Call Scheduled for Thursday, November 14, 2013, at 10:00 am EST — ROCKVILLE, Md., Nov. 7, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious […]

Company’s Proprietary Oral Beta-Lactamase Enzyme Successful Evaluation Conducted by FUJIFILM Diosynth Biotechnologies UK Limited ROCKVILLE, Md., Oct. 15, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today the successful completion of the protein expression evaluation with regard to the

ROCKVILLE, Md., Sept. 20, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, has issued a response to the recent report issued by the Centers for Disease Control and Prevention (CDC) earlier this week that detailed the growing threat of antibiotic-resistant “super

ROCKVILLE, Md., Sept. 10, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that Jeffrey Riley, CEO, will present at the First Global Life Sciences Conference to be held on September 16-17, 2013 in Warsaw, Poland. Mr. Riley is scheduled to

ROCKVILLE, Md., June 19, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that Jeffrey Riley, CEO, will present at the 6th Annual OneMedForum New York Conference on Thursday, June 27, 2013 at The Metropolitan Club in New York

ROCKVILLE, Md., May 15, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today reported financial results for the three months ended March 31, 2013 and summarized operational highlights. Operational Highlights Emphasis on C. difficile (C. diff) Infection Prevention (SYN-004) In the

ROCKVILLE, Md., April 19, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, reiterated that the Exclusive Channel Collaboration Agreement dated August 6, 2012 between the Company and Intrexon Corporation (Intrexon) remains in effect, as stated earlier today. This Exclusive Channel Collaboration

— Strengthening Infectious Disease Portfolio to Include C. difficile, Pertussis and Acinetobacter Targets — ROCKVILLE, Md., April 16, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today reported financial results for the year ended December 31, 2012 and summarized recent operational

ROCKVILLE, Md., March 12, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today that its Chief Executive Officer, Jeffrey Riley, will present at the 25th Annual ROTH Conference being held on March 17-20, 2013 at the Ritz-Carlton, Laguna Niguel in Dana

— The University of Texas at Austin to Join in Pertussis Research Efforts — ROCKVILLE, Md. and SAN FRANCISCO, Dec. 20, 2012 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, and Intrexon Corporation, a leading synthetic biology company that utilizes its proprietary technologies to provide